CUGH and NCI Cervical Cancer Webinar Series Episode 1: Overview of the Global Initiatives in Cervical Cancer Control

July 29, 2020
11:00am EDT

Marleen Temmerman, MD, PhD, MPH, Professor and Chair, Department of Obstetrics and Gynaecology and Director Women’s Health, Faculty of Health Sciences, Aga Khan University, Kenya

Julie Torode, PhD, Director of Special Projects, Union for International Cancer Control, Switzerland

Isaac F. Adewole, MD, Professor, Obstetrics and Gynaecology, University of Ibadan, Nigeria

Anne F. Rositch, MSPH, PhD, Associate Professor, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, U.S.A

Moderator

NCIGlobalHealth@mail.nih.gov
@NCIGlobalHealth
www.cancer.gov/about-nci/organization/cgh

info@cugh.org
@CUGHnews
@CUGH_TAC
www.cugh.org
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and the Consortium of Universities for Global Health. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

None of the faculty/planners have any relevant relationships with ACCME-defined commercial interests.

If you registered for CME credits, you will receive an email with instructions after the webinar.
Cervical Cancer Elimination: An introduction to the global cervical cancer control challenge, updates, progress, and initiatives

Every Country Can Eliminate Cervical Cancer

Julie Torode, PhD
Director, Special Projects, Union for International Cancer Control
CUGH/NCI Global Cervical Cancer Webinar Series, July 2020
Cervical cancer – a preventable cancer, but one with gross inequities between and within countries (Globocan 2018)

Each year:
approx. 600,000 incident cases & over 300,000 deaths

HPV / HIV co-infection
Women living with HIV are 6 times, more likely to develop cervical cancer!
WHO life course approach to cervical cancer control

Primary Prevention
Secondary Prevention
Tertiary Prevention

Global guidelines ✓ Global Indicators ✓ Global Cost-effectiveness recommendations ✓

EQUITY            INTEGRATION            QUALITY OF CARE
“We have the tools to prevent, detect early and cure this disease. I am calling for coordinated action globally to confine cervical cancer to the history book”
Fast-track through the WHO Executive Board

144th EB: More than 70 countries sponsored the decision for WHO secretariat to develop a Global Strategy towards the Elimination of Cervical Cancer

146th EB: Revised strategy noted and supporting resolution with 50 countries co-sponsoring

Due to be adopted at World Health Assembly in May 2020, but change due to covid-19 pandemic

Silence procedure initiated and adoption due on 23rd July 2020
The global strategy

**VISION:** A World Free of Cervical Cancer
**THRESHOLD:** < 4 cases of cervical cancer per 100,000 women per year

### 2030 CONTROL TARGETS

- **90%**
  - of girls fully vaccinated with HPV vaccine by 15 years of age

- **70%**
  - of women screened with an HPV test at 35 and 45 years of age

- **90%**
  - of women identified with cervical disease receive treatment for precancerous lesions or invasive cancer

**4/100,000 means**
cervical cancer rates below that of rare cancers

Focus on coverage for equitable access and outcomes – “leaving no one behind”

**SDG 2030:** Target 3.4 – 30% reduction in mortality from cervical cancer
Cervical Cancer Elimination: Conceptual Framework

Brisson, Canfell and Kim et al. The Lancet 2020; 395: 575-590 and 590-603

90:70:90 is challenging for us, but African communities stand to uniquely benefit from taking up the elimination challenge”

Brazzaville consultation May 2019
Elimination: rates of cervical cancer mortality

Average, 78 LMIC

15M lives saved by 2030

70M cx cancer cases averted

62M women’s deaths averted

Scale-up of vaccination, screening and treatment according to WHO targets
Australia: On-track to eliminate cervical cancer

Predicted timing 2028 (range 2021-2035)

- USA – will try to be first
- Canada 2040

Other national commitments to elimination: Zambia; Malaysia; Kenya; Bhutan; Rwanda ……

We have the strategy and resolution

Now we need governments to make public commitments to their populations
Building momentum: Regional advocacy, technical assistance and best-practice platforms on scaling to 90:70:90

- PAHO Taskforce on cervical cancer elimination
- ECCO call to action on eliminating HPV-caused cancers
- Indo-Pacific ECHO platform
- Francophone women's cancer partnership
Brazil: Building multi-stakeholder networks with national reach
Malaysia: Leap-frog old service models to harness innovations

The new cervical screening test:
- Regular cervical screening tests save lives.
- ONE QUICK SWIPE: to detect viruses that can cause cervical cancer with RESULTS WITHIN 3 DAYS.
- Simple, Painless, Effective, Do-It-Yourself.
- Spare 5 minutes. It could save your life.
- If you are aged 30-65, speak to one of our nurses about testing yourself today.

Conventional health-care professional acquired test

Self-sampling

Conventional Pap test with low sensitivity, requiring repeat testing and robust quality control:
- 50% sensitivity

HPV DNA testing: Higher sensitivity, automation and more objective, MORE cost effective:
- 90% sensitivity

Uses Information communication technology and mobile technology.

Significant attrition to follow-up with current processing workflow between clinics and centralized lab.

Malaysia: Leap-frog old service models to harness innovations
Kenya: Working close to and with the community
Thank you

Dr Julie Torode
Director, Special Projects
torode@uicc.org
www.uicc.org

Courtesy of the Hewlett Foundation

Union for International Cancer Control
31-33 Avenue Giuseppe Motta, 1202 Geneva, Switzerland
T: +41 (0)22 809 1811  F: +41 (0)22 809 1810
E: info@uicc.org  www.uicc.org
Initial feedback on the impact of covid-19 on cervical cancer services

HPV vaccination programmes have been reduced and largely stopped

Screening have largely been stopped with significant fears that this will lead to a shift in stage at diagnosis and thousands of life years lost

Challenges to the safety of LEETZ/LEEP to treat larger precancers

Surgery experiencing major delays

Cancer centres report that despite a return to routine, patients are staying away

The indirect economic impacts are causing ripples in staffing levels, access to key medicines and commodities (eg access to radioactive source for brachytherapy) and a widening of existing inequities

Clear indications that we need to plan for recovery or the post-covid 19 normal (not business as usual)

Are there silverlinings?
Better public/policy-maker understanding of the link between infection & life-threatening disease
Role of testing/vaccines/apps
Potential to build capacities and human capital for eg HPV testing and covid-19 testing in parallel
Building Capacity to Control Cervical Cancer in Nigeria: A Case Study.

Isaac F. Adewole, FAS, FRCOG, FNAMed, DSc(Hons)
Professor of Obstetrics and Gynaecology,
College of Medicine,
University of Ibadan,
Ibadan, Nigeria
If.adewole@comui.edu.ng/ifadewole@gmail.com
Greetings from my base – The University of Ibadan and University College Hospital, Ibadan, Nigeria
The CC Challenges in Nigeria & other Developing countries

Need for rapid Assessment and Prioritization

Current Status in Care

Expansion in Surgical Access

Expansion in Radiotherapy Services

Expansion in Chemotherapy Access

Improvement in Palliative Care

Conclusion/Recommendations
IDENTIFIED CHALLENGES IN MANAGING WOMEN WITH INVASIVE CERVICAL CANCER

- Lack of screening
- Low index of suspicion by Physicians
- Late presentation (seeking alternative care)
- Inadequate facilities (human & nonhuman)
- Financial limitations
- Fear of treatment outcome
Limited cervical cancer and screening implementation in LIMC countries...

Cervical cancer screening coverage for women (25-64 years)

The Urgency to address Cervical Cancer in AFRO

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual deaths</td>
<td>60,757</td>
<td>81,687</td>
</tr>
<tr>
<td>Mortality Trend (1990-2015)</td>
<td>69%</td>
<td>45%</td>
</tr>
<tr>
<td>SDG Agenda</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>Annual Investment</td>
<td>USD $12 billion or probably more</td>
<td>❓❓❓</td>
</tr>
</tbody>
</table>
Effective cancer care requires functional service delivery across a continuum, from the community to the cancer center.

Breakdowns at each step lead to patients leaking out of the pathway and failing to complete cancer treatment.
Launched in 2006

- Establish a nationwide screening program for Nigeria
- Establish Centers of Excellence for the management of Pre-invasive and invasive lesions of the cervix.
- Strengthen national capacity to undertake world class research
PLAN OF ACTION FOR OSCC

PHASE 1

- DEVELOP A PROTOCOL
- ADD ON- VIA/I
- COLPOSCOPE
- LEEP
- CRYOTHERAPY
- CAPACITY BUILDING-SURGERY
- OUTREACH
- EVALUATION

PHASE 2

- HPV VACCINATION
- CAPACITY BUILDING-SURGERY
- CYTOSERVANT
- CHEMOTHERAPY
- RADIOTHERAPY
- MOBILISATION
- AWARENESS
- RESOURCES
- EVALUATION
Stop Cervical Cancer in Nigeria
February 2006...The Beginning
Challenges

- Meeting with Health Minister
- Subsidization of cost of screening
- Upgrade radiotherapy facilities (more/better)
- Access to Chemotherapy
- Strengthening Cancer Registry
- Integration of HPV Vaccination into Routine immunisation
We focused attention on MNCH, EMTCT, Cancers and Public Health Emergencies.......Nov 2015

<table>
<thead>
<tr>
<th>Maternal and Neonatal Mortality Reduction</th>
<th>Elimination of Mother to Child Transmission of HIV</th>
<th>Cancer Prevention, Treatment and Care</th>
<th>Emergencies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Integrated programmatic approach</td>
<td>Programmes Integration</td>
<td>Advocacy</td>
<td>Coordination of actors</td>
</tr>
<tr>
<td>Adopt and scale-up</td>
<td>Scale-up proven approaches</td>
<td>Develop National Framework</td>
<td>Create awareness</td>
</tr>
<tr>
<td>low cost, high impact interventions</td>
<td></td>
<td></td>
<td>Resource Mobilization</td>
</tr>
<tr>
<td>Demand creation</td>
<td>Demand creation</td>
<td>Adoption of international best practices</td>
<td></td>
</tr>
<tr>
<td>Resource mobilization</td>
<td>Private sector engagement</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Radiotherapy Challenges

Infrastructure (few obsolete machines)

Investment in technology (private Sector)

Capacity (limited personnel with knowledge gaps)

Investment in Training & Collaboration

Per-Capita Expenditure on Health

Affordable Healthcare

NGR 114
SA 593
OECD 3484

Late Detection

Late presentation & Diagnostic gaps

Awareness/Education
Few machines with rapid failure and long down time

- 4 functional Linear Accelerators
- Some End – of – Life machines
- 2 functional Cobalt tele machine
- 1 RT treatment unit to 40 million Nigerians

Accessibility to care and Increasing Demands

- Number of Linacs are not adequate to meet demands
- High cost of care, majorly Out of Pocket (OOP)
- High mortality, from poor access and poor early diagnosis (late presentation)

Capacity for Multi-disciplinary teams

- Clinical skill gaps
- Need for training programs following global trends
- Lost time and high cost of short training time abroad
Low Dose Rate Brachytherapy Centres in Nigeria

Low Dose BT

1. FMC Gombe – *Limited Functionality (source logistics problems)*

2. Ahmadu Bello University Teaching Hospital, Zaria (ABUTH) – *Currently Inactive*
Active **Cobalt** External Beam Centres in Nigeria

1. Eko Hospital, Lagos - *Presently Functional*

2. University College Hospital (UCH) Ibadan - *Presently Functional*

3. Ahmadu Bello University Teaching Hospital, Zaria (ABUTH) – *Presently Non-Functional*
New Features on all Future Linac Purchases In Nigeria

<table>
<thead>
<tr>
<th>Feature</th>
<th>Purpose</th>
<th>Benefits</th>
</tr>
</thead>
<tbody>
<tr>
<td>VMAT</td>
<td>Shorter treatment times, faster patient throughput</td>
<td>Lower overall patient exposure</td>
</tr>
<tr>
<td>Min of 120-160 MLC’s</td>
<td>Conforming dose delivery to tumour size and shape</td>
<td>Spare healthy tissues</td>
</tr>
<tr>
<td>Cone Beam CT (Xvi)</td>
<td>Visualize soft tissue structures, target volume and the position of critical structures in realtime on treatment couch</td>
<td>Motion Treatment, High conformance, Increased confidence</td>
</tr>
<tr>
<td>3D (&amp;4D - motion) Planning &amp; Treatment</td>
<td>Image guided optimised treatment planning</td>
<td>Improved treatment quality and better outcomes</td>
</tr>
</tbody>
</table>
National Hospital Abuja, Radiotherapy Centre x 2 Linacs

**Linac 1**

*Year Installed: 2017*

*Equipment Summary:*
- **Model:** Elekta Synergy;
- **Specification:**
  - Multiple Photon & Electron Energies
  - 3D
  - 80 MLC
  - Magnetron Energy Generator
SNEPCo / National Hospital Abuja, Radiotherapy Centre-Linac 2

Linac 2

Year Installed: 2018

Equipment Summary:
- Model: Elekta Synergy;
- Specification:
  - Multiple Photon & Electron Energies
  - 3D
  - IMRT
  - VMAT
  - 160 MLC – Agility
  - Magnetron Energy Generator
COMMISSIONING OF CANCER CENTRE AT NATIONAL HOSPITAL ABUJA BY THE WIFE OF THE VICE PRESIDENT
1ST PATIENT TREATED 1ST DECEMBER 2017
NSIA/ LUTH Cancer Centre

Year Installed: 2018

Equipment Summary:
- Model: Varian Vitalbeam x 2
- Specification:
  - Photon & Electron Energies
  - 3D
  - 120 MLC
  - Klystron Energy Generator
NSIA/ LUTH Cancer Centre

Year Installed: 2018

Equipment Summary:
• Model: Varian Halcyon;
• Specification:
  • Single Photon Energy
  • 3D
  • 120 MLC
  • VMAT
  • Magnetron Energy Generator
COMMISSIONING OF LUTH/NSIA CANCER CENTRE
,FEB 2019,LAGOS BY PRESIDENT BUHARI
Active Radiotherapy Centres in Nigeria - Public Sector

National Hospital Abuja
Elekta Synergy 160MLC Linac + VMAT

University of Nigeria Teaching Hospital (UNTH) – Functional Precise Treatment System
Upgrade to an Elekta infinity HD (PPP) – Process ongoing

NSIA –LUTH Cancer Centre Lagos
Vital Beam X2
Halcyon X1
Gamma Med X1

University of Benin Teaching Hospital (UBTH)
Upgrade to an Elekta infinity HD (PPP) – Process ongoing

Usman Danfodiyo University Teaching Hospital UDUTH Sokoto (Elekta Precise)
High Dose Rate Brachytherapy Centres in Nigeria

**Being Installed or Bunker under construction**

1. University College Hospital (UCH) Ibadan
2. National Hospital Abuja (NHA)
3. Lagos University Teaching Hospital (LUTH)
4. Ahmadu Bello University, Zaria (ABUTH)
5. Usman Danfodiyo University Teaching Hospital (UDUTH), Sokoto
Upcoming Centres in Nigeria and Equipment
Type – Public & Private (6 – 36 months)

- Lakeshore Cancer Center Lagos
  - Elekta Infinity X1
  - Synergy X1
  - Brachytherapy X1

- Marcelle Ruth Cancer Center Lagos
  - Vital Beam X1
  - Synergy X1
  - Brachytherapy X1

- Kaduna State Govt., Kano
  - Elekta Synergy Linacs X2
  - Varian Vital Beam X2
  - Halcyon X1

- Kano State 300 Beds Project, Kaduna
  - Elekta Synergy Linacs X2
  - Varian Vital Beam X2
  - Halcyon X1

- Prevevac Cancer Centre, Lagos
  - Varian Clinac X2

- Jabi Lake Hospital
  - Elekta Infinity X1
  - Flexitron Brachy X1

- Private Hospital Abuja
  - Elekta Infinity x1
  - Flexitron Brachy X1

- Mecure Cancer Centre, Lagos
  - Varian Clinac x2

- Asi-Ukpo Cancer Calabar
  - Elekta Compact Linac
Current Status in Chemotherapy

Choice of Systemic Drug
- Traditional Chemotherapy; widely in-country used historically
- Biologic Therapy – increased adoption in 2019
- Immunotherapy – low adoption, requires higher competency for utilization
- Choice of drug is also largely a function of ability to pay and physician skillsets

Availability, Accessibility, Affordability & Efficacy
- High cost of chemotherapy drugs
- No public sector central procurement
- Payments for drugs mostly out-of-pocket
- Accessibility usually tied to proximity with Teaching Hospital and Federal Medical Centres
- Average Nigerian has limited access to global standards
- Innovation brands like Bayer & Astra Zeneca pulled out of Nigeria in 2016
- Heavy parallel market activity; India & UK (sometimes low efficacy due to poor quality poor storage &/or handling
- High prices also attributable to distributor channel pricing

Policy & Regulation
- No standardized treatment guidelines except for Breast (widely adopted)
- Clinton Health Access Initiative (CHAI); negotiating prices with American companies on behalf of Nigerian Government based on aggregated volume consumption from Tertiary Institutions
- Need for training programs & capacity development following global trends
- Lost time and high cost of short training time abroad
- Partial coverage under National Health Insurance Scheme
- Poor import regulation – reason for strong parallel import market
100+ African cancer experts collaborated with NCCN to harmonize 46 standard treatment guidelines, including cervical cancer

www.nccn.org/harmonized
Systemic therapy: Chemotherapy Access Partnership

Context

- Originally announced in 2017
- 16 high-quality chemotherapies available at access pricing
- 6 countries included

Results to date

- Over 2x average volume growth across 3 procuring countries
- Savings of 56% seen thus far across 4 procuring countries
- Quality shift from 4% to 54% of procured drugs overall
Innovation in Nigeria under the Chemotherapy Program

Problem Statement

Frequent stock outs of chemotherapies at public hospitals drive patients to the private sector where they face high prices and uncertain quality.

Solution

An integrated system with the following features:

- Institutionalized quantification process that enables predictable demand
- 7 hospitals jointly procure affordable, high quality chemotherapy
- Products supplied directly from manufacturer’s local distributor to hospital pharmacy, minimizing markups and delays; patient payments remitted to distributor
- Electronic system enables visibility on real-time payments, demand and available stock
Results to date

- Drugs are now available at access prices at all 7 hospitals
- Nigeria is expected to save $16M annually with coordinated hospital procurement and quadruple the volumes of medicines procured
New agreements announced in June 2020

- 20 products approved by a stringent regulatory authority will now be available on the market in 23 countries in Sub-Saharan Africa
- **Includes complete first-line regimens for cervical cancer**
- Countries expected to save average of 59% over current prices

<table>
<thead>
<tr>
<th>Nigeria</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Anastrozole</td>
</tr>
<tr>
<td>- Carboplatin</td>
</tr>
<tr>
<td>- Cytarabine</td>
</tr>
<tr>
<td>- Doxorubicin</td>
</tr>
<tr>
<td>- Fluorouracil</td>
</tr>
<tr>
<td>- Leucovorin</td>
</tr>
<tr>
<td>- Paclitaxel</td>
</tr>
<tr>
<td>- Bicalutamide</td>
</tr>
<tr>
<td>- Cisplatin</td>
</tr>
<tr>
<td>- Daunorubicin</td>
</tr>
<tr>
<td>- Epirubicin</td>
</tr>
<tr>
<td>- Gemcitabine</td>
</tr>
<tr>
<td>- Methotrexate</td>
</tr>
<tr>
<td>- Tamoxifen</td>
</tr>
<tr>
<td>- Capecitabine</td>
</tr>
<tr>
<td>- Cyclophosphamide</td>
</tr>
<tr>
<td>- Docetaxel</td>
</tr>
<tr>
<td>- Filgrastim</td>
</tr>
<tr>
<td>- Letrozole</td>
</tr>
<tr>
<td>- Oxaliplatin</td>
</tr>
</tbody>
</table>
To expand and sustain the success of this work, we have formed a new alliance to expand access to high-quality cancer treatment in Africa.
Cancer Guidelines Navigator

Oncologists input information about a particular case and are directed to detailed recommendations and prescribing information from the NCCN Harmonized Guideline for Sub-Saharan Africa

https://www.alliedagainstcancer.org/tools
FACILITATORS

- A Network or Multi-disciplinary Working Group is needed
- It is a Long Distance Race
- Champions are needed
- High Level Commitment and Action very critical
- Long Term Funding required
- Capacity Building is Needed
- Data is critical
- International support essential
EFFORTS/RESPONSE TO CHALLENGES

• Government –
  ▶ Increase in no of cancer centres;
  ▶ procurement of additional machines;
  ▶ employment of oncologists vis-à-vis gyne, radiation, medical oncologists etc
SOCIETIES/TRAINING INSTITUTIONS

**SOGON** used her conference last year to discuss gynecologic cancers. Produce Practice Guidelines on CC prevention in 2018.

**WACS** used her conference this year to channel pathway for cancer management across West African sub-region.

**GOSON** –
- Organised nationwide screening for premalignant lesions this year.
- Also has a training workshop for all doctors in Northeast in March 2020 on Colposcopy.
- Now organizes 2-weekly webinar on management of gynecologic cancers.
NGOs

- ABC in Ibadan, IFAF in Ibadan, Joyce John Cancer Foundation in Abakaliki and several others have been working largely on prevention and/or early detection of CC
- Pink Oak Cancer Trust offers full payment for care of indigent patients with early disease

- **DONORS** – facilitation research activities as well as training of personnel in the care of women with ICC

- **INDIVIDUALS** – several individuals have also supported patients’ care
Cervical Cancer (CC) is Preventable
Screening and Vaccination are critical strategies in the control of CC
Capacity for Treatment must be built
Requires meticulous planning, start-up financing
Promote both economic and non-economic benefits
Cervical cancer elimination is feasible
Acknowledgements

- CUGH-NCI
- Michele Folen & OSCC
- Clare Omatseye & JNCI
- Seth Berkley & Gavi
- Meg O’Brien & African Cancer Coalition
- Julie Torode & UICC
- My Colleagues-Drs. Awolude/Oluwasola & Morhason-Bello/Residents/Students
- FMoH/FGN
Opportunities for integrating cervical cancer control interventions into existing global health programs

Marleen Temmerman, MD, OB/GYN, MPH, PhD
Aga Khan University, Nairobi, Kenya
Cervical cancer: a growing threat

Women living with HIV are at 4 to 5 times greater risk of developing cervical cancer.

416,000 estimated cervical cancer-related deaths by 2035.

Annual causes of death in women

<table>
<thead>
<tr>
<th>Year</th>
<th>Maternal Deaths</th>
<th>Cervical Cancer Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>1985</td>
<td>303,000 (2015)</td>
<td>266,000 (2012)</td>
</tr>
<tr>
<td>2000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2025</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2030</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Women are dying in their prime

Every 2 minutes

a woman dies from cervical cancer

40% greater risk of death due to gender inequality
WHO Cervical Cancer Elimination Initiative

In May 2018, WHO, made a call to action for the elimination of cervical cancer, based on 3 pillars: vaccination against the human papilloma virus (HPV), screening of women at risk, and treatment of women with cervical cancer.
WHO Cervical Cancer Elimination Initiative

• A Call to Action with a Secretariat for this high-level flagship project, at the request of the Executive Board. A strategy has been developed.
• The WHO Cervical Cancer Elimination Initiative aims to equip Member States with the resources and technologies to eliminate cervical cancer as a public health problem.
“Through cost-effective, evidence-based interventions, including human papillomavirus vaccination of girls, screening and treatment of precancerous lesions, and improving access to diagnosis and treatment of invasive cancers, we can eliminate cervical cancer as a public health problem and make it a disease of the past.”

Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization
PRIMARY PREVENTION

Girls 9-14 years
- HPV vaccination
Girls and boys, as appropriate
- Health information and warnings about tobacco use
- Sexuality education tailored to age & culture
- Condom promotion/provision for those engaged in sexual activity
- Male circumcision

SECONDARY PREVENTION

Women >30 years of age
- Screening with a high-performance test equivalent or better than HPV test
- Followed by immediate treatment or as quickly as possible, of pre-cancer lesions

TERTIARY PREVENTION

All women as needed
- Treatment of invasive cancer at any age
  - Surgery
  - Radiotherapy
  - Chemotherapy
  - Palliative care
Screening and Integration of RH services

In many countries, population based screening is still far away and opportunities to integrate cervical cancer screening and treatment in existing health services needs scaling up.

The supermarket for women’s reproductive health: the burden of genital infections in a family planning clinic in Nairobi, Kenya

M Temmerman, N Kidula, M Tyndall, R Rukaria-Kaumbutho, L Muchiri, J O Ndinya-Achola
Establishing clinical services alone will not achieve the desired disease and mortality reduction unless several critical components are in place, including:

- Effective mechanisms for mobilizing women to take up the service.
- Basic health services with adequate staff and supplies.
- Adequate supervision to ensure quality of care is maintained and staff are complying with program guidelines such as target age group and recordkeeping.
- Specialist services at provincial level to manage complicated cases.
- Key indicator data to enable effective program management.

Community mobilization presents many challenges, but the project identified several useful lessons from the research and from feedback provided by participants at many levels:

- *Knowing other women who have been screened* is a powerful determinant in a woman’s decision to be screened and may even offset other barriers.
- Building up knowledge and *support among community leaders* is critical for creating an environment that helps women overcome the natural barriers to screening.
- Outreach strategies that work *through church, school, and women’s group networks* are most effective.
- Reaching eligible women while they are attending health facilities (“in-reach”) is also very effective.
- Since travel is a barrier to many women, it is critical that women who do attend for screening receive timely care and are not turned away.

This review shows that integration of cervical cancer screening and treatment with HIV services using different models of service delivery is feasible as well as acceptable to women living with HIV. However, the descriptive nature of most papers and lack of data on the effect on long-term outcomes for HIV or cervical cancer limits the inference on the effectiveness of the integrated programs. There is a need for strengthening of health systems across the care continuum and for high quality studies evaluating the effect of integration on HIV as well as on cervical cancer outcomes.
The integration of cervical cancer prevention into other health services is a winning opportunity to provide more comprehensive health care for women and girls, and reduce both the incidence and impact of this highly preventable disease. **A key area of intervention is to advance the integration of cervical cancer services within SRH services, including family planning (FP).** Early programmatic experiences indicate significant promise for integration of these two services.\(^vi\) The implementation of integrated services between 2012 and 2017 in Kenya, Nigeria, Tanzania and Uganda resulted in increased use of both services, including increased voluntary uptake of long-acting, reversible contraceptive methods, and treatment of nearly 50,000 women with cervical pre-cancer. Similar **efforts to integrate cervical cancer screening into HIV programs** in sub-Saharan Africa have also demonstrated significant impact, with over 550,000 women living with HIV screened since May 2018. Eighty-six percent of these women were screened for the first time.\(^vii\)
Advancing Universal Health Coverage through Cervical Cancer Prevention & Family Planning Integration:
A Call to Action

We call on global and national policy makers to:
- Commit to timely development of cervical cancer guidelines for the use of evidence-based tools and strategies that will facilitate integration. This is particularly important for new cervical cancer technologies that are shown to improve health outcomes for women and girls while reducing the time and resources required for cervical cancer screening.
- Include comprehensive SRH services, including cervical cancer prevention, in universal health coverage and national health insurance schemes. Reflect these services in plans for the provision of comprehensive primary healthcare.

We call on multilateral institutions and technical partners to:
- Collect robust impact and cost data on integrated programs and services to identify the highest impact and most cost-effective models of integration.
- Develop standardized outcome indicators for SRH/cervical cancer integration programs and commit to their consistent measurement.
- Document and share best practices in the integration of sexual health and cervical cancer prevention services, including supportive policies, effective demand generation strategies, and interventions that reduce provider burden and assure program quality.
Advancing Universal Health Coverage through Cervical Cancer Prevention & Family Planning Integration:  
A Call to Action

We call on financial contributors to:

- Fund programs that evaluate approaches to integration, so as to identify models that generate high impact, are cost effective, and can reach specific populations in variable contexts. These evaluations should identify sustainable models for the inclusion of integrated services within national plans for UHC.

We call on advocates to:

- Broaden efforts to increase political will for SRH programs that encompass the life course and the full span of risk among girls and women. This includes the increased risk of HPV-related cancers, including cervical cancer, among women 30 years and older.
- Call upon policy makers to make a national commitment to eliminate cervical cancer under the World Health Organization’s Cervical Cancer Elimination Strategy.
Despite >20 years recommendations and strategies, only 16% of women in Kenya have been screened for cervical cancer.

- Screening all women in the target age group, followed by treatment of detected precancerous lesions can prevent the majority of cervical cancers.
- Decisions on which screening and treatment approach to use in a particular county or health-care facility are based on various factors, including, potential for loss to follow-up, cost, and availability of the necessary equipment and human resources.
- Every woman in the target age group (25-49 years) should have a cervical cancer screening test performed at least once when most benefit can be achieved.
- HPV testing is recommended as the primary screening method.
- Where HPV testing is not yet available, or loss-to-follow-up is a risk, then Visual Inspection with Acetic acid (VIA) or Visual Inspection with Acetic acid and Visual Inspection with Lugol’s iodine (VIA/VILI) is recommended as the primary screening method.
- A “screen-and-treat” approach is recommended.
- Any suspected cancer case after screening should immediately be referred for diagnosis and treatment of cancer.
Integration of Cervical Cancer Screening and Prevention into HIV-care at the Family AIDS Care and Education (FACES) clinics in Kisumu, Kenya
World Cancer Leaders’ Summit

Cancer and
Universal Health Coverage

15-17 October 2019
Nur-Sultan, Kazakhstan
CUGH and NCI Cervical Cancer Webinar Series Episode 1: Overview of the Global Initiatives in Cervical Cancer Control

July 29, 2020

Q&A

Marleen Temmerman, MD, PhD, MPH,
Professor and Chair, Department of Obstetrics and Gynaecology and Director Women’s Health, Faculty of Heath Sciences, Aga Khan University, Kenya

Julie Torode, PhD
Director of Special Projects, Union for International Cancer Control, Switzerland

Isaac F. Adewole, MD
Professor, Obstetrics and Gynaecology, University of Ibadan, Nigeria

Anne F. Rositch, MSPH, PhD
Associate Professor, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, U.S.A

Moderator

info@cugh.org
@CUGHnews
www.cugh.org

NCIGlobalHealth@mail.nih.gov
@NCIGlobalHealth
www.cancer.gov/about-nci/organization/cgh

Consortium of Universities for Global Health

NIH National Cancer Institute

Nationwide Cancer Institute